BioTechnique

BioTechnique

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioTechnique is a US-based private CRDMO providing specialized sterile injectable manufacturing, particularly for cytotoxic and high-potency therapeutics. Founded in 2008 and headquartered in York, Pennsylvania, the company offers end-to-end services including formulation development, fill-finish, lyophilization, regulatory support, and project management. Its business model is service-based, generating revenue by partnering with pharmaceutical and biotech companies to bring their injectable drug products to market.

OncologyBroad Injectable Therapies

Technology Platform

Integrated aseptic fill-finish and lyophilization platform for sterile injectables, supported by ACE, a proprietary cloud-based Quality Management System (QMS) for real-time compliance and operational visibility.

Opportunities

The growing global market for sterile injectables, especially in oncology and biologics, drives demand for specialized CDMO services.
The trend towards outsourcing and the need for domestic US manufacturing capacity present significant growth opportunities.
Their niche in cytotoxic handling creates a defensible position with higher barriers to entry.

Risk Factors

Revenue is dependent on the success of client drug programs, creating pipeline risk.
The business faces significant regulatory and operational risk, as any major quality failure could halt operations.
Intense competition in the CDMO market and pressure on pricing are persistent threats.

Competitive Landscape

BioTechnique competes in the sterile injectable CDMO space against large global players (e.g., Lonza, Catalent, Baxter) and smaller niche specialists. Its differentiation lies in a focused expertise on cytotoxic/high-potency compounds, an in-house integrated service model, and a US-based location, appealing to clients seeking specialized, responsive partners.